SAN FRANCISCO--(BUSINESS WIRE)--Rezo Therapeutics, a biotechnology company pioneering the integrated mapping of disease networks for precision therapeutics, today announced the appointment of Cristiana Guiducci, Ph.D., as chief scientific officer. Dr. Guiducci previously served as senior vice president of immunology and oncology research of Nurix Therapeutics and has nearly 20 years of experience in oncology and immunology drug discovery research.
“Cristiana brings deep scientific experience in drug discovery and has important expertise in building foundational research teams, identifying drug candidates and laying the groundwork for clinical advancement,” said Nevan Krogan, Ph.D., president and co-founder of Rezo Therapeutics. “Cristiana’s appointment to CSO is an instrumental step for Rezo as we continue to expand our scientific acumen and work towards comprehensive mapping of molecular disease networks to inform the development of a new wave of therapies.”
“After spending my career embedded in advancing research across oncology and autoimmune diseases, I’m looking forward to joining Rezo and contributing to its integrated approach to drug discovery,” said Dr. Guiducci. “The Rezo platform, which integrates AI and machine learning, has the potential to serve an important role in drug development by uniting multiple technologies and tools to increase the understanding of disease networks, novel targets, and therapies. In joining Rezo, I’m thrilled to be part of the cutting edge of drug development.”
Prior to Nurix Therapeutics, Dr. Guiducci spent more than thirteen years at Dynavax Technologies, in which she directed discovery and characterization of drug candidates for both oncology and autoimmune diseases at different points. She eventually served as vice president of oncology research, in which she was responsible for directing all foundational research for the Dynavax immuno-oncology assets. Dr. Guiducci earned bachelor’s and master’s degrees in molecular biology from University of Rome, Italy, a Ph.D. in immunology from the Open University of London, UK, and completed post-doctoral training at National Tumor Institute in Milan, Italy.
About Rezo Therapeutics
Rezo is pursuing an integrated approach to drug discovery that leverages the multiple technologies and tools needed to bring disease networks into focus, pinpointing novel targets and therapies with more clarity. Rezo’s Sequence to Systems to Drugs platform integrates proteomics, genetics, structural biology, chemistry, artificial intelligence and machine learning to create maps of molecular disease networks. Based on the work of the founding team at the Quantitative Biosciences Institute (QBI) at the University of California, San Francisco (UCSF), the company’s mission is to break the mold in traditional drug development, which is slow and often siloed. The company’s initial focus is in oncology, with plans to explore additional therapeutic areas through collaborations and partnerships. To learn more, visit the company’s website at www.rezotx.com or its LinkedIn.
